Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163328 · ClinicalTrials.gov registry record · Phase 4
Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT04163328 is a Phase 4 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 31 participants.
The verdict
NCT04163328, a Phase 4 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
HydroEye® is a dietary omega 3 fatty acid supplement that contains both EPA and DHA, as well as GLA and ALA in the form of black currant seed oil. It also has vitamins A, E, C, B6, and magnesium, many of which are involved in fatty acid metabolism. In 2013, Sheppard et al. tested HydroEye® in dry eye patients who were not contact lens wearers and found that symptoms and corneal smoothness improved in response to HydroEye® supplementation. To date, HydroEye® has not been assessed in patients with contact lens discomfort; therefore, the purpose of this clinical trial is to determine the efficacy of HydroEye® as a treatment for contact lens discomfort.
Interventions
- DRUG HydroEye®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-09-16 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04163328
The ClinicalTrials.gov registry entry for NCT04163328 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HydroEye® is the first listed.
NCT04163328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04163328 about?
NCT04163328 is a clinical study titled "Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort". HydroEye® is a dietary omega 3 fatty acid supplement that contains both EPA and DHA, as well as GLA and ALA in the form of black currant seed oil. It also has vitamins A, E, C, B6, and magnesium, many of which are involved in fatty acid metabolism. In 2013, Sheppard et al. tested HydroEye® in dry ey...
What is the current status of trial NCT04163328?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2022-09-16. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT04163328?
The interventions under investigation include: HydroEye® (DRUG).
Who is sponsoring clinical trial NCT04163328?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.